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Abstract
Exosomes are nanovesicles secreted by virtually all cells. Exosomes mediate the hori-
zonal transfer of various macromolecules previously believed to be cell-autonomous in
nature, including nonsecretory proteins, various classes of RNA, metabolites, and lipid
membrane-associated factors. Exosomes derived from mesenchymal stem/stromal cells
(MSCs) appear to be particularly beneficial for enhancing recovery in various models of
disease. To date, there are over 200 preclinical studies of exosome-based therapies in a
number of different animal models. Despite a growing number of studies reporting the
therapeutic properties of MSC-derived exosomes, their underlying mechanism of action,
pharmacokinetics, and scalable manufacturing remain largely outstanding questions.
Here, we review the global trends associated with preclinical development of MSC-
derived exosome-based therapies, including immunogenicity, source of exosomes, isola-
tion methods, biodistribution, and disease categories tested to date. Although the in vivo
data assessing the therapeutic properties of MSC-exosomes published to date are prom-
ising, several outstanding questions remain to be answered that warrant further preclini-
cal investigation.
K E YWORD S
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1 | INTRODUCTION
Mesenchymal stem/stromal cells (MSCs) have been the subject of
clinical trials since they were first tested as a putative therapeutic in
human subjects in 1995 by Lazarus.1 MSCs have shown very encour-
aging results in preclinical studies investigating their therapeutic appli-
cation in a wide array of disease models and benefit from a stellar
record of safety to date.2,3 Indeed, Mesoblast recently demonstrated
efficacy in their primary outcomes in a recent phase III trial for pediat-
ric graft versus host disease (NCT02336230). SanBio has reported
promising results from a phase II trial of chronic stroke patients
(NCT02448641). However, there have been more late-stage clinical
trials that have fallen short of expectations than there have been
successes to date.4 There are likely several reasons for such differ-
ences observed between MSC preclinical and clinical studies such as
potency, consistency and scale-up manufacturing issues which have
been reviewed elsewhere.4,5
MSCs' therapeutic effects are generally thought to be mediated
through the secretion of a variety of factors including canonical secre-
tory proteins such as cytokines and growth factors, as well as
exosomes6-10 (Figure 1). MSCs act as a localized delivery system by
secreting such factors, which then in turn affect the physiology of
both adjacent and distant responder cells.11-13 As MSCs are sensitive
to their microenvironment, the profile of the therapeutic factors they
secrete can be highly context dependent and may potentially vary
from patient to patient.14 Currently, there is much interest in the
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potential application of the regenerative and immunomodulatory fac-
tors found in MSC conditioned media, especially exosome-enriched
fractions, which are now understood to be key active pharmaceutical
ingredients of MSC-based therapies.15 Exosome-based approaches
may hold some advantages over the administration of some adult
stem cell-based therapies, including increased consistency, enhanced
potency, and greater scalability of manufacturing.15 However, much
more work is needed to establish whether such potential advantages
are reproducible for exosome-based therapies. As such, there is cur-
rently interest in investigating the therapeutic capacity and safety
profile of exosomes derived from MSCs (MEX).16 Published reports of
MEX's therapeutic properties in various animal models have signifi-
cantly increased in recent years, which we review here.17 These
recent studies may portend coming future exosome trials. Indeed, the
first U.S. clinical trial investigating an exosome-based therapy
(NCT03608631) was recently listed in the clinical trials database
(clinicalTrials.gov) by Dr. Gauri Varadhachary at MD Anderson.
2 | EXOSOMES
Exosomes are nanosized, cellularly secreted vesicles, which transport
a variety of classes of proteins, RNA, metabolite, and lipid membrane
components to neighboring and distal cell subpopulations
(Figure 2).18-20 Although the term “exosomes” is most commonly used
to identify such vesicles, the terms “microvesicles” and “extracellular
vesicles” (EVs) are also frequently reported.21 The term “exosomes”
F IGURE 1 Mesenchymal stem/stromal cells secrete
immunomodulatory and regenerative factors, including canonical
secretory protein monomers as well as exosomes. The latter of which
has been the subject of increasing preclinical investigation in recent
years
F IGURE 2 Mesenchymal stem cell-
derived exosomes are packaged with a
diverse profile of macromolecules,
including extracellular, membrane-bound,
cytosolic, and nuclear associated factors
Significance statement
Mesenchymal stem/stromal cells (MSCs) are under clinical
development for the treatment of numerous disease indica-
tions. There is growing interest surrounding the therapeutic
application of purified and concentrated regenerative fac-
tors secreted by MSCs, particularly exosome-enriched frac-
tions (MEX), which are now understood to be key active
pharmaceutical ingredients of MSC-based therapies. The
present study summarizes the current state of preclinical
development of MEX parsed from over 200 peer-reviewed
reports utilizing various animal models. It also discusses
opportunities that may be addressed which would help stra-
tegically advance the field of MEX-based therapeutic
development.
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applies only to the fraction of extracellular vesicles generated via the
endosomal pathway.22 Most reported MSC-derived exosome prepara-
tions contain species other than exosomes, such as vesicles derived
from the budding of the plasma membrane budding (ectosomes,
microvesicles) or through apoptotic cellular disintegration. Due to the
various isolations reported to date, it is feasible that some of these
so-called exosomal fractions may actually represent a minority of the
isolated EVs. As there is currently no accepted manner in which to
prove beyond a shadow of doubt the origin of EVs isolated with cur-
rent technologies, we shall use the term “exosome” here as a proxy
for preparations comprised by extracellular vesicles of diverse origins.
Historically, such factors have been thought to be cell autonomous,
but numerous studies over the past decade have established that
exosomes mediate a highly evolutionarily conserved intercellular com-
munication system.23 Indeed, many of the proteins and mechanisms
associated with exosome biogenesis are conserved down to Gram-
negative bacteria.24 The term “exosome” was coined in 1981, by
Johnstone25 and Stahl groups.26 Exosome biogenesis has been shown to
be associated with distinct intracellular complexes including, the
endosomal sorting complex, tetraspanins, sphingolipid ceramide, and Rab
proteins, which comprise the largest part of the Ras-like small GTPase.27
The multiplicity of the pathways involved in exosome biogenesis may
contribute to their inherent heterogeneity in any given population.28
Exosomes possess notable physiological properties and originate
via the inward budding of endosome membranes, called multivesicular
bodies (MVBs).29 MVBs fuse with the plasma membrane and
exosomes are released into the extracellular milieu, either to be taken
up by target cells residing in the local microenvironment or carried to
distal sites via biological fluids.30 Exosome membranes are enriched in
cholesterol, sphingomyelin, ceramide, and lipid raft components, in
addition to their protein, RNA, and metabolite constituents.31
Exosomes are packaged with an evolutionary conserved set of pro-
teins including tetraspanins (CD9, CD63, CD81), heat-shock proteins
(HSP60, HSP70, HSP90), numerous annexins, and programmed cell
death 6-interacting protein.31 However, exosomes are also packaged
with specific proteins that are representative of their parental cell
source and reflective of their microenvironmental niche.32
Mesenchymal stem cell-derived exosomes (MEX) are generally iso-
lated and purified from media conditioned by MSCs. However, there is
evidence that suggests that the therapeutic effects of MEX batches are
derived from a cacophony of billions of vesicles with both overlapping
factors and distinct factors encompassing their composition.33 The
reported pleiotropic therapeutic effects, therefore, are due to the com-
plex interactions of a variety of factors packaged across MEX subpopu-
lations.34 Consequently, precisely controlled manufacturing of MEX is
needed to ensure interbatch consistency of the resulting product.34
It has yet to be determined whether the protein, RNA, lipid, or
metabolite contents packaged into MEX mediate their observed
therapeutic effects. To date, several studies have focused on the
miRNA content of exosomes as potentially key regulators of their
functional properties.35 However, recent studies have shed light on
the relatively low abundance of exosomal miRNA, with at least one
report indicating that MEX contain several orders of magnitude more
total protein than total RNA.35,36 In addition, MEX are highly
enriched for extracellular proteins.7 Therefore, an increased focus on
the proteins packaged into MEX is warranted. However, the critical
and essential factors that are packaged into MEX that mediate their
immunomodulatory and tissue healing properties have yet to be
robustly characterized. It is likely that the culture conditions under
which MEX are manufactured greatly influence the proteins pack-
aged into them, just as MSCs respond by modifying the growth fac-
tors and cytokines they secrete in response to various priming
conditions.37 However, to date few studies have robustly explored
such lines of investigation, and it remains unclear as to whether pro-
teins detected in most exosome preparations are contained within or
attached to the outside of the vesicles.38,39 Here, we review the
common trends reported in over 200 peer-reviewed preclinical stud-
ies of MSC-derived exosomes/microvesicles/extracellular-vesicles
listed in the PubMed database (Supporting Information Table S1).
3 | MEX IMMUNOGENICITY
Numerous studies have established the low immunogenicity of MEX
administered as both a single bolus as well as with repeated doses.
MEX have also been observed to have similar hypoimmunogenic
F IGURE 3 The diversity of, A, species, B, tissue source, C,
isolation technique, D, culturing methods, E, disease indication, and F,
route of administration represented from over 200 preclinical reports
on exosomes derived from mesenchymal stem cells. Abbreviations:
BM, bone marrow; ESC, embryonic stem cell; FBS, fetal bovine serum;
HPLC, high pressure liquid chromatography; IM, intramuscular; IP,
intraperitoneal; iPSC, induced pluripotent stem cell; IV, intravenous;
MSK, musculoskeletal; PL, placenta; precip, precipitation; SC,
subcutaneous; TFF, tangential flow filtration; UC, ultracentrifugation;
UC, umbilical cord; WJ, Wharton's jelly
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properties as well. Comprehensive proteomic analysis of MEX has not
detected major histocompatibility complex (MHC) I or MHC II com-
plex to date.6 Indeed, 65% of the >200 in vivo studies published to
date have administered MEX derived from human sources into a wide
variety of animal models of disease, mostly in mice (Figure 3A). No
explicit immunogenicity has been reported in any of these species
crossing studies. Therefore, MEX may be considered hypo-
immunogenic, in a similar fashion to their cells of origin, MSCs. Cur-
rent evidence for the hypoimmunogenic nature of MEX includes at
least one study that investigated repeated doses of MEX in mice,
which did not observe any overt toxicity according to hematologic
and blood chemistry analyses, as well as in-depth histopathological
evaluation of several different tissues.40 Similarly, toxicity has not
been observed with repeated dosing of exosomes derived from other
fibroblasts and Hek293 cells.40,41 However, further studies are
required to validate that the apparent hypoimmunogenicity properties
of MEX are reproducible across different disease models and dosing
regimens.
4 | MEX SOURCES AND PURIFICATION
METHODS
The tissue source for parental MSCs for MEX studies have been iso-
lated from a variety of tissues, including bone marrow (51%),
umbilical/placental tissues (23%), and adipose tissue (13%), derived
from embryonic or induced pluripotent stem cells (8%), or others (5%;
Figure 3B). The most common exosome isolation method used to
purify MEX from conditioned media to date has been ultracentrifuga-
tion (72%), followed by precipitation methods (23%; Figure 3C).
Unfortunately, ultracentrifugation does not scale easily and also cau-
ses processing associated damage to MEX due to the extreme forces
involved, thereby limiting the value of such an approach for preclinical
studies.42 Precipitation methods are even more problematic as it is
widely accepted that such methods coisolate many contaminants,
especially when used in conjunction with serum containing media, as
most such studies report.43 Such differences in the tissue source and
exosome isolation techniques undoubtedly affect both the packaging
and observed functional properties of the resulting MEX isolates.
Consequently, substantial caution is warranted when interpreting and
comparing such preclinical MEX studies and their reported outcomes.
To increase the translatability of future MEX preclinical studies inves-
tigators should give strong consideration to these issues. For example,
industry-appropriate manufacturing and isolation methods such as
ultrafiltration and the use of serum-free isolation media would greatly
enhance the value of preclinical studies assessing MEX therapeutic
properties, mechanisms of action (MoA), and safety profile.
Approximately 55% of MEX studies used precleared fetal bovine
serum (FBS)-containing media, while 45% of published reports used
serum-free or chemically defined media (Figure 3D). Due to the
potential for coisolation of residual FBS exosomes, as well as FBS-
derived protein aggregates, it may be advantageous to use serum-free
isolation media to diminish the possibility of introducing bovine-
derived artifacts.7 However, the optimum media constituents required
to manufacture MEX with maximum potency has yet to be deter-
mined, and may vary according to the target disease.
5 | MEX BIODISTRIBUTION
The vast majority of preclinical animal studies of MEX's therapeutic
effects have used systemic routes of administrations. Consequently,
establishing the pharmacokinetics of EV systemic administration is
required for their successful progression through preclinical devel-
opment. To date, there is a dearth of studies that have investigated
the biodistribution patterns and kinetics, especially within the con-
text of relevant pathophysiology. Several studies have investigated
the biodistribution patterns of fluorescently labeled MEX.40,44-46
Based on these published reports, systemically administered MEX
appear to be cleared within a few hours and generally ultimately
accumulate within the liver and spleen. However, these studies have
largely focused on biodistribution associated with healthy, wild-type
animals, which does not take into account the distinct underlying
pathophysiology associated with individual diseases. For example,
several published reports have demonstrated that exosomes are
capable of crossing the blood-brain barrier (BBB) when active neu-
roinflammation is present.47-49
Neuroinflammatory cascades often result in the compromised
integrity of the BBB, thereby allowing for large macromolecules and
even cells to enter from the periphery.50,51 In addition, some methods
of manufacturing and labeling MEX use extended processing times,
which may decrease their resulting functional properties. This may be
a key point if it is determined that MEX uptake by specific cellular
populations is mediated by receptor mediated endocytosis, as some
proteins are more labile than others. Special consideration should also
be given to the methods chosen for labeling MEX for biodistribution
studies.
To date only a few studies have investigated the biodistribution
patterns and kinetics of systemically administered exosomes. These
studies have often relied on lipid-incorporating fluorescent dyes
together with in vivo optical imaging (eg, IVIS).40,45,46,52 This
approach is based on the assumption that lipid incorporating dyes
remain embedded in EV membranes for the duration of the study.
However, several studies have demonstrated that up to 75% of such
dyes dissociated from vesicles, when incubated in plasma.53,54 In
addition, these commonly used dyes can spontaneously form EV-
like particles.54 Radiolabeling of exosomes presents an alternative
imaging strategy; however, few published reports have investigated
the biodistribution of postinserted radiolabeled EVs.55,56 An alterna-
tive labeling method of engineering MEX with Cre-recombinase in
Lox reporter mice has been reported, but it remains unclear whether
such engineering methods modulate the functions of the resulting
vesicles.48,57,58 Taken together, the field could benefit from contin-
ued investigation of the MEX pharmacokinetics that take these fac-
tors into account. Finally, given that the labeling procedures
themselves often require substantial manipulation of EVs, the
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validation of the resulting labeled exosomes would be an insightful
control. The continued investigation of MEX's therapeutic targets
in vivo is likely critical to successful translation of this technology to
the clinic.
6 | DISEASE CATEGORIES OF MEX
PRECLINICAL STUDIES
The pleiotropic nature of both MSCs and MEX-based therapies allows
for the feasibility of their assessment in a wide range of disease
models. There are now over 200 published reports of MEX therapeu-
tic properties in vivo, which span numerous disease categories. Neu-
rological (16%), cardiovascular (12%), immunological (12%), and kidney
(10%) diseases represent the four most investigated areas of disease,
respectively (Figure 3E). A significant portion of studies used animal
models of musculoskeletal (10%), liver (9%), and pulmonary (8%) dis-
eases (Figure 3E). However, it would greatly benefit the MEX field to
continue to establish their putative MoA.
The robust characterization of MEX's MoA would allow for
shrewdly designed release criteria, relevant potency assays, and open
future avenues of research investigating the biological underpinnings
of responders versus nonresponders.59,60 Such determinations are
likely highly dependent of the tissue source of parental MSCs, donor-
to-donor variation, manufacturing, and isolation methods used, as well
as the specific pathophysiology involved in a particular disease.4 How-
ever, there also lies the potential for there to be broad overlapping
observations across these variables. For example, many of these disor-
ders involve a substantial inflammatory component, which may be
ameliorated by MEX-based therapy. MSCs and MEX have been
reported to possess anti-inflammatory properties in both preclinical
and clinical studies. Increasing the granularity of our understanding of
the molecular underpinnings of these affects would increase the ratio-
nale for the preclinical investigation of MEX as a putative therapeutic
platform technology.
There exists a substantial degree of heterogeneity in dosing regi-
mens applied across these published reports the bridge both small and
large animal models (route of administration, number of doses, quan-
tity of dose, how dose is calculated, etc.; Supporting Information
Table S1). Consequently, the optimization of dosing regimens (eg,
repeated dosing, dose range finding, disease specific routes of admin-
istration, etc.) should be investigated in greater depth (Figure 3F).
7 | DISCUSSION
It is now well established that exosomes are biological agents central
to intercellular communication and possess therapeutic potential.
Although it is of interest to the field, there exists a paucity of studies
that have attempted to directly compare MSC efficacy to that of
exosomes purified from MSC-conditioned media. Indeed, the methods
used for such studies comparison studies require some consideration,
such as the requisite thawing of cryopreserved product immediately
prior to administration, which is not common in preclinical studies, but
a necessary supply chain aspect of cell-based therapies. In addition,
some contemplation on what constitutes an equivalent dose is appro-
priate in light of the fact that methods for the purification of
exosomes isolated from conditioned media are not 100% efficient.
Ultimately, such comparisons may be best viewed in terms of the cost
of goods for each prospective approach necessary to reach an equiva-
lent clinical outcome.
Another confounding factor is the fact there are reports, which
describe inconsistent results. Such inconsistencies are likely the result
of the different culturing methods used prior to and during exosome
harvests, as well as variances in the purification techniques used.
Therefore, further process development of exosome-based therapies
utilizing scalable production methods, and standardized operating pro-
cedures are needed to advance the field forward. Such methodologies
likely affect the cargo and downstream functional properties of the
resulting exosomes in significant ways. In addition, the development
of appropriate release criteria and relevant, potency assays would
benefit from robust follow-up studies elucidating putative, disease-
specific MoA. Lessons learned from the MSC field about the critical
need to develop robust potency assays and release criteria provide
valuable insight to MEX researchers. There exists the potential that
release criteria developed for exosome-based therapies may be more
robust as they are not dynamic living medicines, but rather EVs pack-
aged with a static payload of therapeutic factors. Taken together, the
preclinical development of MEX-based therapies has advanced con-
siderably in the last few years, as interest in this therapeutic platform
technology continues to grow. It is feasible that the MEX field may
use the considerable insights to be gained from both the clinical suc-
cesses and barriers to commercialization experienced by MSC-based
drug developers.
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